Skip to content

Workplace-based HIV Self-testing Among Men in Uganda (WISe-Men)

Workplace-based HIV Self-testing (HIVST) and Linkage to Care or Prevention Services Among Men in Private Security Services in Uganda: A Cluster Randomized Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04164433
Enrollment
548
Registered
2019-11-15
Start date
2020-02-01
Completion date
2021-01-31
Last updated
2020-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

HIV self-testing, Men, Workplace, Security Services, Linkage

Brief summary

This study seeks to determine whether workplace delivery of HIV self-testing will lead to an increase in uptake of HIV testing and subsequent linkage to care or prevention services among men in Uganda.

Detailed description

The current coverage of HIV testing and counseling in Uganda is 60% with only 34% of these being men and only about 55% of males living with HIV know their status (MoH, 2016). The challenges with HIV testing require a new focus and new approaches to reach people with undiagnosed HIV infection. HIV self-testing (HIVST) is one such innovative approach to making testing more accessible to several under-served populations such as men and key populations (WHO, 2013). In this regard, this study seeks to determine whether providing HIVST in workplace settings will increase the uptake of HIV testing services among men employed in private security services in Uganda and improve linkage to treatment and prevention services. Design: Cluster randomized trial in two Ugandan districts Participants: Male employees of private security companies

Interventions

DEVICEOral HIV Self-Test (OraQuick)

The oral HIV self-test is a device for taking a test which is painless. The user gently swipes the test swab along the upper gums once and the lower gums once. The swab is then inserted inside the test tube provided and results are ready in 20 minutes.

Sponsors

Makerere University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

Eligibility Criteria: * 18-60 years old * Employed \>6 months in the private security company * Men who have not tested for HIV before * Men who tested HIV \>one year ago

Design outcomes

Primary

MeasureTime frameDescription
HIV self-testingWithin one month of the interventionProportion of men who self-report testing after receiving a kit at the workplace

Secondary

MeasureTime frameDescription
Linkage into HIV care and confirmatory testing following HIV self-testingmeasured at 1 and 3 months after interventionProportion of participants who self report confirmatory testing from a health facility for all participants with a reactive-self test
Consistent condom use following HIV self-testingmeasured at 1 and 3 months after interventionProportion of participants who use a condom for each sexual encounter in a month.
Initiation of Antiretroviral Therapy (ART) following a confirmatory HIV testmeasured at 1 and 3 months after interventionProportion of participants who self report ART initiation following a positive result from a confirmatory HIV test result or evidence of an ART card. Data will be collected using a questionnaire.
Uptake of Voluntary Male Medical Circumcision (VMMC) following HIV self-testingmeasured at 1 and 3 months after interventionProportion of previously uncircumcised participants who self report Voluntary Male Medical Circumcision (VMMC).
Uptake of PrEP by Most-At-Risk Populations (MARP) following HIV self-testingmeasured at 1 and 3 months after interventionProportion of participants considered as Most-At-Risk Populations (MARP) who initiate Pre-exposure prophylaxis (PrEP)

Countries

Uganda

Contacts

Primary ContactPatience Muwanguzi, PhD
pamuwanguzi@gmail.com+256777036811

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026